Please login to the form below
Inviragen
This page shows the latest Inviragen news and features for those working in and with pharma, biotech and healthcare.
Sanofi's dengue vaccine could debut in 2015
Takeda is also developing a vaccine against dengue fever that was acquired along with other candidates when it took over Inviragen last year in a deal valued at up to $250m.
Latest news
-
Takeda buys vaccines specialist Inviragen
The biopharma company Inviragen, which has operations in the US and Singapore, will receive an upfront payment of $25m, and development and commercial milestones of up to $215m. ... In addition to its dengue vaccine, Takeda will also acquire the rights
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch table for May 2013
UAE based regional company $40m $244m option for 52%. 284. Inviragen/ Takeda.
-
Pharma deals during May 2013
targets from Abide; Takeda's $250m acquisition of Inviragen; GSK's $325m acquisition of the vaccine platform technology company, Okairos; and BMS's $112m licence for antibody conjugates from Ambrx. Note
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Client Services Director- Flexible Working
-
Negotiable
- Account Manager – Healthcare advertising
-
Salary TBC
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director – UK Office
-
Excellent salary and benefits
-
Senior Medical Writer
-
Competitive salary plus benefits
-
Events Executive
-
DOE
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- AbbVie/Allergan's merger faces public opposition
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Report: Customer experience, shaping digital healthcare
- The benefits of uniting in a divergent environment
- Encouraging signs in biomarker R&D
- J&J puts pressure on rivals with new Erleada okay in prostate cancer
- Pharma exhibition stand design with added value
- Bluebird Bio reveals further encouraging data for CALD gene therapy
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
